FreeStyle Libre 3 Continuous Glucose Monitoring System

Diabetes Mellitus Clinical Trial

Official title:

FreeStyle Libre 3 Continuous Glucose Monitoring System Confirmation Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05962710
• Other study ID #: ADC-US-VAL-22221
• Status: Terminated
• Start date: January 27, 2023
• Est. completion date: January 31, 2023

Study information

• Verified date: June 2022
• Source: Abbott Diabetes Care
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to characterize the FreeStyle Libre 3 Continuous Glucose Monitoring System performance with respect to YSI reference venous plasma sample measurements.

Description:

This is a pivotal, non-randomized, single arm, multi-center, prospective, nonsignificant risk study to evaluate the FreeStyle Libre 3 Continuous Glucose Monitoring System accuracy and safety. Up to 80 adult subjects (18 years of age or older) and up to 80 pediatric subjects (2-17 years of age) subjects will be enrolled at up to six (6) clinical research sites in the United States. Each subject will wear two sensors for 15 days.

Interstitial glucose readings from each Sensor will be obtained with a corresponding smart phone. Subjects will do up to six (6) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1). Based on the subjects' age and/or weight, subjects will have up to three (3) in- clinic visits during which intravenous blood draws and YSI reference testing will occur.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: January 31, 2023
• Est. primary completion date: January 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

1. Subject must be at least 2 years of age.

2. Subject must have type 1 or type 2 diabetes.

3. Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections or inhalations (at least 3 daily).

4. Subject must be able to read and understand English.

5. In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.

6. At the time of enrollment, subject must be available to participate in all study visits.

7. For subjects age 2 to 5: willing to allow medical personnel to perform up to 16 capillary fingersticks to allow for capillary blood samples to be obtained per the study protocol.

8. For subjects age 6 and older: willing to allow medical personnel to insert an IV catheter in the arm to allow for venous blood samples to be obtained per the study protocol.

9. Subjects aged 18 years and older must be willing and able to provide written signed and dated informed consent.

10. Subjects aged 17 years and younger must have a parent, guardian or legally authorized representative willing and able to provide written informed consent.

11. Subjects aged 7 - 17 years must be willing and able to provide written signed and dated informed assent.

Exclusion Criteria:

12. Subjects age 18 and older: Subject is known to be pregnant, attempting to conceive or is not willing and able to practice birth control during the study duration (applicable to only to female subjects age 18 and older).

13. Subjects age 17 and younger: Subject is known to be pregnant or becomes pregnant during the study (only applicable to female subjects age 17 years and younger)

14. Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.

15. Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.

16. Subject is currently participating in another clinical trial.

17. Subject has donated blood within 60 days prior to the beginning of the study activities.

18. For subjects aged 6 years and older: subject has a hemoglobin (Hb) level that is 10% or more below the normal range (for reference the low end of the normal range for Hb for adult males is 12.6 g/dL and for adult females is 11.7 g/dL1; for pediatric males and pediatric females aged 6 - 9 years it is 11.5 g/dL1; for pediatric males and pediatric females aged 10 - 12 it is 12.0 g/dL1; for ; for pediatric males aged 13 - 14 it is 12.0 g/dL and pediatric females aged 13 - 14 it is 11.5 g/dL1; and for pediatric males and pediatric females aged 15 - 17 it is 11.7 g/dL1)

19. Subject has a known concomitant medical condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff.

20. Subject has X-ray, MRI, CT or diathermy appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.

21. Subject is unsuitable for participation due to any other cause as determined by the investigator.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• FreeStyle Libre 3
FreeStyle Libre 3 Continuous Glucose Monitoring System

Locations

Country	Name	City	State
United States	Rocky Mountain Diabetes & Osteoporosis Center	Idaho Falls	Idaho
United States	Rainier Clinical Research Center	Renton	Washington
United States	Diabetes and Glandular Disease Clinic	San Antonio	Texas
United States	Sansum Diabetes Research Institute	Santa Barbara	California

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Diabetes Care

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	System Performance	System Performance will be characterized with respect to YSI reference venous plasma measurements	46 days